The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 349-356.e13, February 2010

Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma

  • Margaret M. Kelly, MB, PhD, FRCPC

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Firestone Institute for Respiratory Health, Department of Pathology and Molecular Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
    • These authors contributed equally to this work.
  • ,
  • Terence M. O'Connor, MB, FRCPI

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • These authors contributed equally to this work.
  • ,
  • Richard Leigh, MB, PhD, FRCPC

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
  • ,
  • Joceline Otis, MLT

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
  • ,
  • Carol Gwozd, MLT

      Affiliations

    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
  • ,
  • Gail M. Gauvreau, PhD

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
  • ,
  • Jack Gauldie, PhD

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Pathology and Molecular Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
  • ,
  • Paul M. O'Byrne, MB, FRCPC, FRCPI

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationAddress for reprints: Paul M. O'Byrne, MB, FRCPC, HSC 3 W10, McMaster University, 1200 Main St West, Hamilton, Ontario L8N 3Z5, Canada.

Received 8 February 2009; received in revised form 2 September 2009; accepted 8 September 2009. published online 07 December 2009.

Background

Combining inhaled corticosteroids with long-acting β2-agonists results in improved asthma symptom control and fewer asthma exacerbations compared with those seen after inhaled corticosteroids alone. However, there are limited data as to whether these beneficial effects are due to enhanced anti-inflammatory actions or whether such combination therapies affect airway remodeling in patients with asthma.

Objective

We sought to determine the effects of inhaled budesonide/formoterol combination therapy versus inhaled budesonide alone or inhaled placebo on allergen-induced airway responses, airway inflammation, and airway remodeling.

Methods

Fourteen asthmatic subjects with dual responses after allergen inhalation were included in this prospective, randomized, double-blind, 3-period crossover study. Outcomes included early and late asthmatic responses, changes in airway responsiveness, sputum eosinophilia measured before and after allergen challenge, numbers of airway submucosal myofibroblasts, and smooth muscle area measured before and after study treatment.

Results

Allergen-induced sputum eosinophilia was significantly reduced by combination treatment to a greater extent than by budesonide alone. Allergen inhalation resulted in a significant increase in submucosal tissue myofibroblast numbers and produced a significant decrease in percentage smooth muscle area. Combination therapy, but not budesonide monotherapy, significantly attenuated these changes in myofibroblast numbers and smooth muscle area.

Conclusions

The effects on allergen-induced changes in sputum eosinophils, airway myofibroblast numbers, and smooth muscle seen with combination therapy suggest that the benefits associated with this treatment might relate to effects on airway inflammation and remodeling. The attenuation of early asthmatic responses and airway hyperresponsiveness by combination treatment was likely due to the known functional antagonistic effect of formoterol.

Key words: Bronchial provocation tests, bronchoscopy, biopsy, inhaled glucocorticoids, long-acting inhaled β-agonists

Abbreviations used: AHR, Airway hyperresponsiveness, α-SMA, α-Smooth muscle actin, ICS, Inhaled corticosteroid, IQR, Interquartile range, LABA, Long-acting β2-agonist, MCh, Methacholine

 

 Supported by an unrestricted grant from AstraZeneca, Lund, Sweden.

 Disclosure of potential conflict of interest: T. M. O'Connor receives research support from AstraZeneca Ireland. R. Leigh is a consultant for AstraZeneca Canada, GlaxoSmithKline, Novartis Pharmaceuticals Canada, and Boehringer-Ingelheim Canada; is on the speakers' bureau for AstraZeneca Canada, GlaxoSmithKline, and Novartis Pharmaceuticals Canada; and receives research support from Novartis Pharmaceuticals Canada, MedImmune, Ception, Merck-Frosst Canada, Schering-Plough, and Bayer. G. M. Gauvreau receives grant support from Schering-Plough and MedImmune. P. M. O'Byrne is on the Advisory Board for AstraZeneca, GlaxoSmithKline, Topigen, Wyeth, and Schering-Plough; is on the speakers' bureau for AstraZeneca and GlaxoSmithKline; and receives research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering-Plough, and Alexion. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01340-2

doi:10.1016/j.jaci.2009.09.011

The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 349-356.e13, February 2010